Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Essock, S. M. Articles by Lieberman, J. A. Search for Related Content PubMed Citation Articles by Essock, S. M. Articles by Lieberman, J. A. Schizophrenia Spectrum Disorders Atypical Neuroleptics Related Article

Effectiveness of Switching Antipsychotic Medications

OBJECTIVE: Changing antipsychotics is common despite the dearth of information on risks and benefits associated with medication changes. The authors examined phase 1 findings from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study to explore whether it was more advantageous to continue taking the medication being received at baseline or to switch to a different antipsychotic. METHOD: First, for patients randomly assigned to treatment with olanzapine (N=314) or risperidone (N=321), the authors assessed the impact of being assigned to stay with the medication they were receiving at entry into the study versus being assigned to switch to these medications from a different antipsychotic. Second, for patients whose baseline antipsychotic was olanzapine (N=319), risperidone (N=271), or quetiapine (N=94), the authors examined the impact of being randomly assigned to stay with the same antipsychotic versus switch. Finally, the authors assessed the impact of removing the data of 209 patients whose random assignment was to stay with their baseline antipsychotic. The authors followed analysis strategies for CATIE; primary outcome was time until all-cause treatment discontinuation. RESULTS: Individuals randomly assigned to olanzapine and risperidone who were continuing with their baseline medication had significantly longer times until discontinuation than did those assigned to switch antipsychotics. When these "stayers" were removed, differences seen in the original CATIE phase 1 analyses were attenuated, although the original pattern of results remained. CONCLUSIONS: Comparisons of medication effectiveness should take into account whether medications being compared were each newly initiated. Further, unless the clinical situation requires a medication change, prescribers may want to take steps to optimize current medication regimens (e.g., dosage adjustments, behavioral or psychosocial interventions) before switching medications.

Related Article:

In This Issue
Am J Psychiatry 2006 163: 68. [Full Text] [PDF]

This article has been cited by other articles:

				M. S. Swartz, T. S. Stroup, J. P. McEvoy, S. M. Davis, R. A. Rosenheck, R. S. E. Keefe, J. K. Hsiao, and J. A. Lieberman What CATIE Found: Results From the Schizophrenia Trial Psychiatr Serv, May 1, 2008; 59(5): 500 - 506. [Abstract] [Full Text] [PDF]

				W. T. Carpenter and R. W. Buchanan Lessons to Take Home From CATIE Psychiatr Serv, May 1, 2008; 59(5): 523 - 525. [Abstract] [Full Text] [PDF]

				N. H. Covell, M. T. Finnerty, and S. M. Essock Implications of CATIE for Mental Health Services Researchers Psychiatr Serv, May 1, 2008; 59(5): 526 - 529. [Abstract] [Full Text] [PDF]

				J. M. Davis and S. Leucht Has Research Informed Us on the Practical Drug Treatment of Schizophrenia? Schizophr Bull, May 1, 2008; 34(3): 403 - 405. [Full Text] [PDF]

				J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment Schizophr Bull, April 2, 2008; (2008) sbn019v1. [Abstract] [Full Text] [PDF]

				R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak Rethinking Antipsychotic Formulary Policy Schizophr Bull, March 1, 2008; 34(2): 375 - 380. [Abstract] [Full Text] [PDF]

				T. S. Stroup and J. R. Geddes Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals Schizophr Bull, March 1, 2008; 34(2): 266 - 274. [Abstract] [Full Text] [PDF]

				S. Lewis and J. Lieberman CATIE and CUtLASS: can we handle the truth? The British Journal of Psychiatry, March 1, 2008; 192(3): 161 - 163. [Abstract] [Full Text] [PDF]

				S. LEUCHT, S. HERES, J. HAMANN, and W. KISSLING Pretrial Medication Bias in Randomized Antipsychotic Drug Trials Am J Psychiatry, August 1, 2007; 164(8): 1266 - 1266. [Full Text] [PDF]

				R. Tandon, W. T. Carpenter, and J. M. Davis First- and Second-Generation Antipsychotics: Learning From CUtLASS and CATIE Arch Gen Psychiatry, August 1, 2007; 64(8): 977 - 978. [Full Text] [PDF]

				J. C. West, J. E. Wilk, I. L. Muszynski, D. S. Rae, M. Rubio-Stipec, C. L. Alter, W. E. Narrow, and D. A. Regier Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients During the First 4 Months of the Medicare Prescription Drug Benefit Am J Psychiatry, May 1, 2007; 164(5): 789 - 796. [Abstract] [Full Text] [PDF]

				S. Heres, W. Kissling, S. Leucht, and for the Bias in Antipsychotic Studies workgroup Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia Evid. Based Ment. Health, May 1, 2007; 10(2): 56 - 56. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us